Company news
Taysha Gene Therapies, Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 4, 2024
Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients
November 28, 2023
Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
November 13, 2023
Taysha Gene Therapies to Release Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 14
November 6, 2023
Taysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
October 23, 2023
Taysha Gene Therapies Announces Two Poster Presentations on TSHA-102 in Rett Syndrome at Upcoming European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
October 9, 2023
Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome
September 25, 2023
Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy (GAN)
September 18, 2023
Taysha Gene Therapies Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome
August 23, 2023
Taysha Gene Therapies Reports Initial Clinical Data from First Adult Rett Syndrome Patient Dosed in REVEAL Phase 1/2 Trial and Provides Corporate Update with Second Quarter 2023 Financial Results
August 13, 2023
Taysha Gene Therapies Announces $150 Million Private Placement Financing
August 13, 2023
Taysha Gene Therapies Announces Positive Recommendation from Independent Data Monitoring Committee of REVEAL Phase 1/2 Trial in Rett Syndrome
July 30, 2023
Taysha Gene Therapies Provides Clinical Updates for Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome at R&D Day
June 27, 2023
Taysha Gene Therapies to Host Virtual R&D Day on Lead Clinical Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome
June 14, 2023
Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial Under Investigation for the Treatment of Rett Syndrome
June 4, 2023
Taysha Gene Therapies Presents Preclinical Data on TSHA-102 for Rett Syndrome Demonstrating Cellular Regulation of MeCP2 Expression in Key Mouse Models at the American Society of Gene and Cell Therapy 26th Annual Meeting
May 18, 2023
Taysha Gene Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 10, 2023
Taysha Gene Therapies to Release First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11
May 3, 2023
Taysha Gene Therapies Announces Presentation on New Preclinical Data for TSHA-102 in Rett Syndrome at Upcoming American Society of Gene and Cell Therapy 26th Annual Meeting
April 26, 2023
Taysha Gene Therapies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 27, 2023
Taysha Gene Therapies to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 28
March 14, 2023
Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy and a 2023 Corporate Outlook
January 30, 2023
Taysha Gene Therapies Announces Executive Leadership Changes
December 15, 2022
Taysha Gene Therapies to Participate in JMP Securities Hematology and Oncology Summit
November 28, 2022
Taysha Gene Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 7, 2022
Taysha Gene Therapies to Release Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 8
November 1, 2022
Taysha Announces Pricing of Public Offering of Common Stock
October 25, 2022
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock
October 24, 2022
Taysha Gene Therapies to Host Conference Call to Discuss Astellas Pharma’s Strategic Investment to Support the Development of Taysha’s AAV-based Gene Therapy Programs
October 23, 2022
Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha’s AAV-based Gene Therapy Programs
October 23, 2022
Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha's AAV-based Gene Therapy Programs
October 23, 2022
Taysha Gene Therapies Announces Presentations at the Upcoming 29th Annual Meeting of the European Society of Gene & Cell Therapy (ESGCT)
October 5, 2022
Taysha Gene Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 10, 2022
Taysha Gene Therapies to Release Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11
August 8, 2022
Taysha Gene Therapies to Participate in Upcoming August Investor Conferences
July 31, 2022
Taysha Gene Therapies to Participate in Upcoming William Blair Biotech Focus Conference 2022
July 5, 2022
Taysha Gene Therapies Announces Annual Stockholder Meeting
June 12, 2022
Taysha Gene Therapies to Participate in Upcoming June Investor Conferences and Convention
June 1, 2022
Taysha Gene Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 15, 2022
Taysha Gene Therapies to Release First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 16
May 10, 2022
Taysha Gene Therapies Announces Presentations at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy
May 9, 2022
Taysha Gene Therapies Receives Orphan Drug Designation from the European Commission for TSHA-120 for the Treatment of Giant Axon Neuropathy (GAN)
May 2, 2022
Taysha Gene Therapies Announces Oral Presentations at the Upcoming 2022 IRSF Rett Syndrome Scientific Symposium and the ASCEND National Summit
April 24, 2022
Taysha Gene Therapies to Participate in Upcoming Chardan Genetic Medicines and Cell Therapy Manufacturing Summit
April 17, 2022
Taysha Gene Therapies Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 30, 2022
Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-102 in Rett Syndrome
March 28, 2022
Taysha Gene Therapies to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 31
March 23, 2022
Taysha Gene Therapies to Participate in Upcoming April Investor Healthcare Conferences
March 22, 2022
Taysha Gene Therapies to Participate in the Oppenheimer 32nd Annual Virtual Healthcare Conference
March 7, 2022
Taysha Gene Therapies Announces Positive Safety Data from UT Southwestern-Sponsored Clinical Trial for the Treatment of CLN7 Batten Disease at 18th Annual WORLDSymposium
February 8, 2022
Calls
The 5 newest of 22 calls. Every call is listed under its year.
- Taysha Gene Therapies (NASDAQ:TSHA) Q3 2026 Earnings Call
Nov 12, 2026
Transcript - Taysha Gene Therapies (NASDAQ:TSHA) Q2 2026 Earnings Call
Aug 11, 2026
Transcript - Taysha Gene Therapies (NASDAQ:TSHA) Q1 2026 Earnings Call
May 6, 2026
Transcript - Taysha Gene Therapies (NASDAQ:TSHA) Q4 2025 Earnings Call
Mar 19, 2026
Transcript - Taysha Gene Therapies (NASDAQ:TSHA) Q3 2025 Earnings Call
Nov 4, 2025
Transcript
Decks
The 5 newest of 9 decks. Every deck is listed under its year.
- Investor Presentation (August 2026)
Investor deck · 43 slides · August 2026
- Corporate Update (June 2026)
Corporate update · 28 slides · June 2026
- Q1 2026 Earnings Presentation
Earnings · 41 slides · May 6, 2026
- Q2 2025 Earnings Presentation
Earnings · 25 slides · Aug 12, 2025
- Corporate Update (May 2025)
Corporate update · 28 slides · May 28, 2025